Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Total Assets
Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) holds total assets worth CN¥14.22 Billion CNY (≈ $2.08 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shijiazhuang Yiling Pharmaceutical Co Lt shareholders equity for net asset value and shareholders' equity analysis.
Shijiazhuang Yiling Pharmaceutical Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shijiazhuang Yiling Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shijiazhuang Yiling Pharmaceutical Co Ltd's total assets of CN¥14.22 Billion consist of 32.6% current assets and 67.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.4% |
| Accounts Receivable | CN¥1.52 Billion | 11.4% |
| Inventory | CN¥1.75 Billion | 13.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.07 Billion | 8.0% |
| Goodwill | CN¥109.51 Million | 0.8% |
Asset Composition Trend (2008–2024)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Shijiazhuang Yiling Pharmaceutical Co Lt worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shijiazhuang Yiling Pharmaceutical Co Ltd's current assets represent 32.6% of total assets in 2024, a decrease from 53.6% in 2008.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2024, down from 15.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 3.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 13.1% of total assets.
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Shijiazhuang Yiling Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.57 | 2.44 |
| Quick Ratio | 1.28 | 1.08 | 1.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.54 Billion | CN¥2.25 Billion | CN¥3.22 Billion |
Shijiazhuang Yiling Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shijiazhuang Yiling Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -21.6% |
| Total Assets | CN¥13.32 Billion |
| Market Capitalization | $4.17 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shijiazhuang Yiling Pharmaceutical Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shijiazhuang Yiling Pharmaceutical Co Ltd's assets decreased by 21.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total assets of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥13.32 Billion ≈ $1.95 Billion |
-21.56% |
| 2023-12-31 | CN¥16.98 Billion ≈ $2.48 Billion |
+3.94% |
| 2022-12-31 | CN¥16.34 Billion ≈ $2.39 Billion |
+26.59% |
| 2021-12-31 | CN¥12.90 Billion ≈ $1.89 Billion |
+12.29% |
| 2020-12-31 | CN¥11.49 Billion ≈ $1.68 Billion |
+26.72% |
| 2019-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
+5.99% |
| 2018-12-31 | CN¥8.56 Billion ≈ $1.25 Billion |
+8.49% |
| 2017-12-31 | CN¥7.89 Billion ≈ $1.15 Billion |
+26.19% |
| 2016-12-31 | CN¥6.25 Billion ≈ $914.64 Million |
+9.52% |
| 2015-12-31 | CN¥5.71 Billion ≈ $835.11 Million |
+12.17% |
| 2014-12-31 | CN¥5.09 Billion ≈ $744.52 Million |
+9.23% |
| 2013-12-31 | CN¥4.66 Billion ≈ $681.62 Million |
+11.82% |
| 2012-12-31 | CN¥4.17 Billion ≈ $609.58 Million |
-1.41% |
| 2011-12-31 | CN¥4.23 Billion ≈ $618.31 Million |
+138.57% |
| 2010-12-31 | CN¥1.77 Billion ≈ $259.17 Million |
+17.34% |
| 2009-12-31 | CN¥1.51 Billion ≈ $220.88 Million |
+81.44% |
| 2008-12-31 | CN¥831.91 Million ≈ $121.73 Million |
-- |
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfec… Read more